HUM-MOLGEN events: HDL Cholesterol - Metabolic Pathways and Drug Developments

HUM-MOLGEN -> Events -> Meetings and Conferences

HDL Cholesterol - Metabolic Pathways and Drug Developments

January 02, 2003

The Knowledge Foundation, Inc., Cambridge, MA USA
3/2/2003 - 3/4/2003

Raising the low level of HDL cholesterol is a powerful strategy for reducing the risk of cardiovascular diseases. The complex nature of the metabolism of HDL presents a variety of targets for therapeutic intervention.
In it's fourth year, this conference will provide you the latest in the
research of HDL cholesterol metabolic pathways. Hepatic Lipase, Scavenger
Receptor B, ABCA1, Apo A1, PPAR and LXR are all major areas of interest in
the search for new therapeutics. Leading academic and industry experts will
present in-depth analysis on exciting new discoveries such as:

- Biopharmaceutical product candidates for
cardiovascular diseases
- Effect of HDL apo A-I mutations on cholesterol homeostasis
- Antioxidant properties of apo-A-I
- The influence of SR-BI on HDL cholesteryl ester and
free cholesterol
- Hepatic lipase and HDL/LDL heterogeneity
- LXR - and LXR agonists
- Regulation of PPAR g mediated gene expression
- Apo-A-I, ABCA1 and cholesterol efflux

Organized by:

The Knowledge Foundation, Inc.

Invited Speakers:

John Bielicki,
John Brunzell,
Jim Burgess,
Guoquing Cao,
Georges Chang,
Jeffrey Chisholm,
Christopher Fielding,
Richard Karas,
Eric Lund,
Mark McGovern
Charles Meng,
Andrew Nicholson,
James Otvos,
Lisa Patel,
Attilio Rigotti
Ernst Schaefer
Mary Scorci-Thomas
Jonathan Smith,
David Williams

Deadline for Abstracts:

none

Registration:

registration is possible either via phone: 617-232 7400 fax:617-232 9171 online at www.knowledgefoundation.com

E-mail:

meder@knowledgefoundation.com

Posted by:

Margit Eder

Host:

141.149.163.2